SCHEMBL7603753

SCHEMBL7603753

Nc1ncccc1-c1nnc(Cc2ccc(OCc3ccccc3)cc2)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
HPGD P15428 5/20 0.50
NPC1 O15118 5/20 0.50
L3MBTL1 Q9Y468 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 4/20 0.47
MAPK1 P28482 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 2/20 0.47
THRB P10828 1/20 0.47
PKM P14618 1/20 0.47
GPR55 Q9Y2T6 1/20 0.46
LTA4H P09960 1/20 0.45
MAPK14 Q16539 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.43
MAOB P27338 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606886 0.89 L3MBTL1 (0.46) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL26686648 0.86 SMN1; SMN2 (0.44) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL1733657 0.84 TDP1 (0.45) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL1733770 0.83 HPGD (0.47) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL7604839 0.81 RAB9A (0.47) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL1733488 0.79 RAB9A (0.51) RAB9ASMN1; SMN2NPC1L3MBTL1TDP1
SCHEMBL26686786 0.77 RAB9A (0.38) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL30047547 0.76 LTA4H (0.58) RAB9ASMN1; SMN2NPC1L3MBTL1LTA4H
SCHEMBL1734090 0.76 LTA4H (0.46) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL7606984 0.75 GAA (0.51) RAB9ASMN1; SMN2HPGDNPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265607-A1 AMINOPYRIDINE COMPOUND AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2023-10-25 EP disclosed
US-8183264-B2 Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same Eisai R&D Managment Co., Ltd. (JP) 2012-05-22 US disclosed
US-8183264-B2 Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same Eisai R&D Managment Co., Ltd. (JP) 2012-05-22 US disclosed
US-20110201649-A1 AGRICULTURAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-18 US disclosed
US-20110201649-A1 AGRICULTURAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-18 US disclosed
US-20100099718-A1 PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-22 US disclosed
US-20100099718-A1 PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-22 US disclosed
EP-2065377-A1 PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME Eisai R&D Management Co., Ltd. (JP) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201649-A1 AGRICULTURAL COMPOSITION H1-0, H1-3, H1-2 RAB9A 164/4885SMN1; SMN2 4604/4885HPGD 1474/4885
US-20100099718-A1 PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME ERG28, CBR3, CBR1 RAB9A 1677/4885SMN1; SMN2 4143/4885HPGD 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.